title: [Prognostic value of PSA kinetics in locally advanced prostate cancer treated by maximal androgen blockade combined with brachytherapy].
abstract: OBJECTIVE
  To evaluate the effect of post-treatment PSA kinetics on the prognosis of prostate cancer (PCa).
  
  
  METHODS
  We retrospectively reviewed the clinical data of 114 cases of locally advanced PCa treated by maximal androgen blockade (MAB) combined with brachytherapy, and analyzed the association of the changes in PSA kinetics with the prognosis of the patients.
  
  
  RESULTS
  The median survival time of the patients was 81 (15 - 144) months, with 1-, 3- and 5-year survival rates of 91. 23%, 78.07% and 68.42% , respectively. Univariate analysis indicated that the baseline PSA level, PSA nadir, the time of PSA decreasing to nadir, PSA doubling time, and the extent of PSA declining were all predictive factors for the survival time of the PCa patients. Multivariate analysis demonstrated that PSA nadir, the time of PSA decreasing to nadir, and the extent of PSA declining were three independent prognostic factors, which prolonged the long-term survival of the patients by 1.7, 3.2 and 6.8 times, respectively.
  
  
  CONCLUSIONS
  For locally advanced PCa treated by MAB combined with brachytherapy, PSA nadir <1 micro g/L, the time to nadir <3 months, and the extent of PSA declining >96% are independent prognostic factors.
authors.forename: Yong
authors.initials: Y
authors.lastname: Luo
authors.forename: Neng-Bao
authors.initials: NB
authors.lastname: Wei
authors.forename: Jia-Hui
authors.initials: JH
authors.lastname: Zhao
authors.forename: Xin-Hao
authors.initials: XH
authors.lastname: Cui
authors.forename: Ming-Chuan
authors.initials: MC
authors.lastname: Li
authors.forename: Yun-Hua
authors.initials: YH
authors.lastname: Lin
authors.forename: Zhu
authors.initials: Z
authors.lastname: Hou
authors.forename: Yi-Li
authors.initials: YL
authors.lastname: Han
authors.forename: Yong-Guang
authors.initials: YG
authors.lastname: Jiang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000728:Androgens / Q000008:administration & dosage* / Q000627:therapeutic use; D001918:Brachytherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D000728:Androgens; D017430:Prostate-Specific Antigen